Dr. Arthur Manda | Therapeutic Platform Architect & Designer | Founder, Artlin Health™

Dr. Arthur Manda is a pharmaceutical scientist, biotech strategist, and designer of sovereign health infrastructure. His work sits at the intersection of translational science, nervous system intelligence, and platform execution, where biological insight becomes institutional resilience.

Trained in RNA therapeutics, advanced drug delivery, and small-molecule development, Dr. Manda designs and develops the platforms that power the next generation of biological and computational therapeutics. His work sits at the intersection of molecular innovation, predictive modeling, and translational execution, enabling faster, safer, and more scalable drug and genome-editing solutions.

Recent projects include:

Lipid–polymer nanoparticles (LPNPs) for siRNA delivery to cancer cells,

demonstrating precision gene silencing in oncology models.

Peptide/lipid-associated nucleic acids (PLANAs) for CRISPR/Cas9 ribonucleoprotein delivery,

advancing cutting-edge genome editing platforms.

AI-driven predictive modeling for drug development,

including neural network approaches to anticipate formulation and process effects, accelerating translational decisions and reducing experimental risk.

Targeting Breast Cancer: The Familiar, the Emerging, and the Uncharted Territories,

exploring innovative strategies across oncology pipelines.

Artificial neural network–based inference of drug–target interactions,

demonstrating the integration of computational inference with nanotechnology for precision therapeutics.

Through the fusion of experimental design, hybrid nanoparticle engineering, and AI-driven predictive modeling, Dr. Manda architects transformative platforms at the intersection of biology, AI, and frontier technology, turning complex molecular systems into scalable, high-impact ventures.

His approach doesn’t just advance molecules, it builds infrastructure for high-impact therapeutics and resilient organizations, bridging deep science with practical execution. This is next-generation biotech at the frontier of molecular, computational, and systems-level design, ready to power founders and companies with scalable, high-value solutions.

But it is his recognition of founder physiology as infrastructure that sets his work apart.

Across biotech and therapeutic development, he observed that failure points often emerged not from flawed science, but from exhausted operators. Burnout, stress dysregulation, and leadership fragmentation were not side effects; they were structural vulnerabilities.

In response, Dr. Manda designed the Resilience Design School™, a nervous system–coded capacity-building platform engineered to support biotech founders, health architects, and translational leaders in navigating complexity, pressure, and strategic execution.

Through his broader platform, Artlin Health™, and its verticals like Artlin Launch Studio™, Dr. Manda is building a sovereign biotech ecosystem that unites molecular execution with human infrastructure, preparing founders not only to launch therapeutics, but to lead resiliently.

His work supports the design of next-generation health systems, starting with the biology of the people who build them.

Because the nervous system is the real CEO.
And biotech infrastructure begins there.